Elsevier

Clinical Lung Cancer

Volume 10, Issue 4, July 2009, Pages 244-248
Clinical Lung Cancer

Original Contribution
Utility of Integrated Computed Tomography—Positron Emission Tomography for Selection of Operable Malignant Pleural Mesothelioma

https://doi.org/10.3816/CLC.2009.n.033Get rights and content

Abstract

Background

Malignant pleural mesothelioma (MPM) is a primary malignancy characterized by local invasion of the pleura and metastasis. Despite advances in computed tomography (CT) and magnetic resonance imaging (MRI), accurately staging patients remains challenging. Recent studies have examined the use of integrated CT—positron emission tomography (PET) for staging patients.

Materials and Methods

Mayo Clinic databases were queried to identify cases with a histologic diagnosis of MPM from 2000 to 2006. Inclusion criteria were a diagnosis of MPM, an available CT scan, and an initial staging integrated CT-PET scan. A total of 35 patients were identified who met the inclusion criteria. Computed tomography and integrated CT-PET scans were reviewed by experienced radiologists. Laboratory parameters were reviewed. The Mayo Clinic tumor registry and Social Security database were queried for survival data in patients in which no follow-up was available.

Results

Findings on integrated CT-PET excluded 14 of 35 patients from surgical intervention. Extrapleural pneumonectomies (EPPs) were performed in 8 patients, and partial pleurectomies were performed in 2 patients. Upstaging from integrated CT-PET occurred in 70% of the patients when surgical pathology was available, 2 cases to an inoperable stage. Although not statistically significant, median survival was 20 months for patients undergoing an EPP and 12 months for patients excluded from surgical intervention by integrated CT-PET.

Conclusion

Malignant pleural mesothelioma is a difficult disease to accurately stage. The most common reason for upstaging in our series was an increase in T (tumor; tumor-node-metastasis staging system) disease. Our data suggest that integrated CT-PET is excellent for detecting nodal and distant metastases. However, the ability of this imaging modality to correctly stage locoregional disease is not superior to the combination of CT and MRI as reported in the literature.

References (26)

  • DB Schneider et al.

    Positron emission tomography with F18-Flourodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma

    J Thorac Cardiovasc Surg

    (2000)
  • T Treasure et al.

    Mesothelioma: benefit from surgical resection is questionable

    J Thorac Oncol

    (2007)
  • B Price et al.

    Mesothelioma trends in the United States: an update based on surveillance, epidemiology and end results program data for 1973 through 2003

    Am J Epidemiol

    (2004)
  • Cited by (49)

    • FDG PET/CT for Staging and Restaging Malignant Mesothelioma

      2022, Seminars in Nuclear Medicine
      Citation Excerpt :

      However, the fact that PET/CT relies on functional/metabolic information rather than appearance, determines the major advantage of the modality with respect to morphological imaging, since typical CT findings consisting in pleural nodules, pleural thickening with or without lung encasing, can be highly sensitive (sensitivity 94%-100%), but tend to be poorly specific for MPM (specificity 36%-51%).3,16,42 This advantage of metabolic imaging with [18F]FDG PET/CT determines also its ability to better stage MPM (Fig. 1), leading to a direct impact on patients management16 ranging from 20% to 40% of the cases.43-46 In fact, various authors have reported a significantly superior diagnostic performance for PET/CT compared to CT alone,46-48 particularly for diffuse chest disease, mediastinal lymph nodes and extra-thoracic localizations, for which the modality shows sensitivities of 100%, 88%, and 100%, respectively (Table 2).

    • FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma

      2022, Seminars in Nuclear Medicine
      Citation Excerpt :

      NCCN guidelines recommend 18F FDG PET/CT prior to surgery in clinical stage 1-3A and epithelioid histology. 18F FDG PET/CT may identify locally advanced tumor, nodal metastases, or extrathoracic metastases, precluding surgery.28 In a study by Erasmus et al 18F-FDG PET/CT precluded surgery in 41% of patients.29

    • Pleural Tumors

      2022, Oncologic Imaging: A Multidisciplinary Approach
    • The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines

      2020, Clinical Radiology
      Citation Excerpt :

      Further, identifying mediastinal nodes on CT is difficult (sensitivity 60% and specificity 70%) as adjacent pleural thickening obscures the lymphadenopathy.4,29,34,68 PET/CT performs better for the detection of nodal disease,69 but the reference standard for staging mesothelioma remains postoperative histological staging and mediastinoscopic sampling of lymph nodes. CT TNM staging is associated with interobserver variability making it is suboptimal in predicting prognosis in patients with MPM.70,71

    • Diseases of the Pleura and Mediastinum

      2019, Abeloff’s Clinical Oncology
    • Uncommon Thoracic Tumors

      2015, Clinical Radiation Oncology
    View all citing articles on Scopus

    This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA.

    Electronic forwarding or copying is a violation of US and international copyright laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.

    Abstract accepted for poster presentation at the American Thoracic Society International Conference in Toronto, Ontario, Canada, in May 2008.

    View full text